News &amp; Updates

The selective neurokinin (NK)-1,3 receptor antagonist elinzanetant appears to be beneficial in the treatment of vasomotor symptoms (VMS) and associated sleep disturbance in postmenopausal women, as shown in the results of the phase IIb SWITCH-1 trial.

Elinzanetant a promising nonhormone treatment option for VMS, sleep problems

Statins reduce MACE in patients with normal MPI, elevated CAC score

Use of moderate to high-intensity statin (MHIS) following myocardial perfusion imaging (MPI) results in fewer major adverse cardiovascular events (MACE) and is independently predictive of 24-month MACE among patients with normal stress MPI and coronary artery calcium (CAC) score >300, a Singapore study has shown.

Statins reduce MACE in patients with normal MPI, elevated CAC score

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

Compared with standard dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy after 1- to 3-month DAPT results in similar rates of fatal and ischaemic events, as well as lower major bleeding risk, regardless of percutaneous coronary intervention (PCI) complexity, according to a study.

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

Twice-yearly maintenance dosing of inclisiran reduces atherogenic lipoproteins for primary prevention of patients with elevated LDL-C* despite statin use, according to the analysis of the primary prevention cohort from the ORION-11 trial.

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

The use of liposomal irinotecan in combination with 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX regimen) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP) in the first-line setting, according to the NAPOLI-3* trial presented at the ASCO GI 2023.

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

$Hyaluronic acid rectal spacer improves safety outcomes of hypofractionated RT for prostate cancer$

Hyaluronic acid rectal spacer improves safety outcomes of hypofractionated RT for prostate cancer

Rectal spacing with hyaluronic acid helps lessen rectal dosimetry and mitigate the gastrointestinal (GI) toxicity associated with hypofractionated radiation therapy (RT) for prostate cancer, according to a study.

Hyaluronic acid rectal spacer improves safety outcomes of hypofractionated RT for prostate cancer

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

13 Feb 2023 by

Antibiotics are usually prescribed by physicians to patients hospitalized with decompensated cirrhosis even without an infection diagnosis, according to a UK study. However, this practice has neither reduced the overall risk of hospital-acquired infections (HAI) nor improved survival.

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

Nitrofurantoin use tied to liver injury, may lead to cirrhosis, death

Long-term exposure to nitrofurantoin (NTF) can result in drug-induced liver injury (DILI), which then increases the risk of parenchymal necrosis, bridging fibrosis, cirrhosis, and death or liver transplantation, reveals a study. In addition, NTF-DILI is associated with HLA-DRB1∗11:04, a risk factor for liver injury.

Nitrofurantoin use tied to liver injury, may lead to cirrhosis, death